News items HIV medicine approved for young children
16 March 2022

For young children with HIV, there is now an effective and safe drug available that inhibits the infection. Researchers at Radboud university medical center have shown that an existing anti-HIV drug, dolutegravir, is also suitable for children under twenty kilograms body weight, with a paediatric tablet containing a lower dose. The World Health Organization WHO has incorporated the findings into its guidelines.

Worldwide, 1.8 million children under the age of 15 are living with HIV, a virus that, without treatment, can eventually lead to AIDS. This virus attacks the body’s own defenses, making pathogens that would normally be stopped dangerous. A cure is not possible at this time, but when using medication people with HIV can live a long life. 

For a long time there was no clear treatment advice for children. Then the ODYSSEY study was started, in which a large group of international scientists searched for the best medication for children. In 2020 this was followed by an advice for children over twenty kilos. Now this advice is also available for smaller children who are living with HIV: those who are at least 4 weeks old and weigh between 3 and 20 kilos. Researchers at Radboud university medical center and others have shown that, in low doses, the drug dolutegravir is easy to use and can safely be prescribed to these children. A special pediatric tablet has been developed by the manufacturer that will also become available in low-income countries. This advice is included in the drug's patient information in Europe and America and in the WHO's treatment guidelines. 

Researcher Angela Colbers, together with Radboudumc colleagues Hylke Waalewijn, Pauline Bollen and David Burger is involved in this study: 'The younger children start taking anti-HIV medication, the better, and in low-income countries we aim to make treatment the same for children and adults. In adults, dolutegravir is mainly used, but for children there was no suitable pill available and the dosage was unknown. Now we know that the new pediatric tablet works well and what dosage to use. Babies from four weeks of age who need it can take this medication safely. The drug produces few side effects, it inhibits virus growth quickly and the risk of resistance is low.'

Dolutegravir is one of three medications children take to combat the virus. 'These drugs tackle a different part of the virus, making them collectively an effective combination,' Colbers says. What's more, it's a relatively inexpensive drug that is widely available: from high- to low-income countries, an important starting point for WHO. 

Curing the virus is not yet any closer, Colbers explains. 'A lot of work is being done on other treatments and also vaccines, but unfortunately without results yet. The corona crisis has had consequences for the fight against HIV, but hopefully the knowledge gathered from the corona vaccines will also have a positive effect on the development of HIV vaccines. That is not yet the case. That's why I'm happy with this treatment advice for the young patients: so that we can treat them as optimal as possible for now.'

About the publications

This study is an additional part of the ODYSSEY study, the findings of which were published in December 2021 in the international journal New England Journal of Medicine. This also concluded, co-authored by Angela Colbers, that the drug dolutegravir works better in children with HIV than the treatment that was the standard of care at the time. 

Publication in The Lancet HIV: Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - Hylke Waalewijn, Man K Chan, Pauline D J Bollen, Hilda A Mujuru, Shafic Makumbi, Adeodata R Kekitiinwa, Elizabeth Kaudha, Tatiana Sarfati, Godfrey Musoro, Annet Nanduudu, Abbas Lugemwa, Pauline Amuge, Cecilia L Moore, Pablo Rojo, Carlo Giaquinto, Angela Colbers, Diana M Gibb, Deborah Ford, Anna Turkova, David M Burger, ODYSSEY Trial Team. DOI:

  • Want to know more about these subjects? Click on the buttons below for more news.


More information

Pauline Dekhuijzen

wetenschaps- en persvoorlichter

send an email

Related news items

Your heart rate as a thermometer Research Olympic athletes will be followed up during 4Daagse

18 July 2022

Body temperature can be determined from heart rate. This is what research by the Radboudumc among Olympic athletes shows. Athletes can use this method during training to eventually perform better in the heat. The technique is now being further investigated among participants in the 4Daagse.

read more

Do insects help 4Days walkers to recover? a Radboudumc study

7 July 2022

During the first 4Daagse since 2019, Radboudumc is investigating whether walkers will benefit from grounded protein-rich insects. It is known that animal proteins contribute to recovery after exercise, but the researchers want to find out whether proteins from insects can do this just as well.

read more

More than five million euros for research to improve palliative care Jeroen Hasselaar will lead research project with Horizon grant

15 June 2022 Jeroen Hasselaar will lead a large international research project. With a 5.3 million euro grant from the EU's Horizon program, he and his team want to improve palliative care for cancer patients, together with partners from nine European countries. read more

New test for Lyme disease is not reliable

15 June 2022 To determine whether someone has Lyme disease, doctors in the Netherlands often use antibody tests. For some time now, so-called cellular tests have been available on the market. However, the VICTORY study published in The Lancet Infectious Diseases has found that these tests are not reliable. read more

With concerted effort, tuberculosis could be eradicated in 30 years time March 24th was World Tuberculosis Day

24 March 2022 Since 2020, the number of deaths from tuberculosis increased for the first time in a decade, caused by the COVID pandemic: fewer people had access to the right care on time. Some catching up is needed. read more